DiabeterResearch

[DiabeterResearch @DiabeterRes]

#CGM/#AID technology is improving #glycemicoutcomes and #QoL in #type1diabetes. In NL, CGM #reimbursement is limited, whereas experiences with CGM/AID use are very positive. Increased support to maximize AID benefits and minimize burdens is warranted”. https://t.co/PCgoRFMZOs

[DiabeterResearch @DiabeterRes]

The basal insulin component as % of the total daily dose of insulin does not change with increasing use of of technology in #T1D treatment. https://t.co/qOKWgLmOxe
#insulintreatment #type1diabetes #SWEET #Diabeter #diabetestechnology #insulinpumps #continuousglucosemonitoring

[DiabeterResearch @DiabeterRes]

Data from the #SWEET registry showed that telemedicine was received positively by both people with #T1D and #healthcareproviders, impacted positively on glycemic outcomes and #complications, and that the effect was not dependent on treatment modality. https://t.co/SwTOifwNcS

[DiabeterResearch @DiabeterRes]

Update: #DiabeterResearch website:
https://t.co/eQz141SGs5
- Cardiovascular risk management in T1D
- Comparison glycemic target achievement between 2010-2012 and 2016-2020
#type1diabetes #diabetes #cardiovascular #cardiovasculardisease #cardiovascularhealth #glycemic #hba1c

[DiabeterResearch @DiabeterRes]

#Insulinpumps have yielded increasingly better results, but there is still a proportion of people with #T1D who discontinue due to various reasons. This review aimed to include the most recent rates of insulin pump #discontinuation and identify reasons: https://t.co/n3XztAbZjQ

[DiabeterResearch @DiabeterRes]

Although sex differences exist in #type1diabetes, less is known about sex influences on childhood #t1d care&outcomes. This review, co-authored by D.Mul&T. Sas of #Diabeter reports sex differences in glycemic control, BMI, insulin doses, DKA& #QOL https://t.co/sBagsbSNfs

[DiabeterResearch @DiabeterRes]

Costs of new technology for #diabetes treatment pose an increasing burden on #HealthCareResources. This publication, co-authored by #Diabeter endocrinologists D.Mul&T. Sas, assessed healthcare resource use&hospital costs in Dutch youths with diabetes https://t.co/fCMRmjySCa

[DiabeterResearch @DiabeterRes]

Update on https://t.co/sq2vxs08cT of #psychology-related publications in which Diabeter psychologist Giesje Nefs was involved: https://t.co/brgJrFUGPG
#diabetes*fear of #hypoglycemia*#Mentalhealth & #lifestylebehaviours * #Bingeeating *#Sleep & #circadianrythm*#cognitivefunction

[DiabeterResearch @DiabeterRes]

A growing group of people with diabetes is using open-source AID systems: #WeAreNotWaiting. Recently a consensus statement on the use of these systems was published. Find out more at the @DiabeterResearch site:https://t.co/ot37MtmKwp

#T1D #type1diabetes #OpenAPS #diabetes

[DiabeterResearch @DiabeterRes]

There are many assays available to measure C-peptide, a proxy for Beta-cell function in diabetes. We found that in many publications reporting on C-peptide the used assay is not mentioned, complicating comparisons of studies.

You can find out more here: https://t.co/ylKVnTTl71

[DiabeterResearch @DiabeterRes]

There are many assays available to measure C-peptide, a proxy for Beta-cell function in diabetes. We found that in many publications reporting on C-peptide the used assay is not mentioned, complicating comparisons of studies.

You can find out more here: https://t.co/ylKVnTTl71

[DiabeterResearch @DiabeterRes]

A growing group of people with diabetes is using open-source AID systems: #WeAreNotWaiting. Recently a consensus statement on the use of these systems was published. Find out more at the @DiabeterResearch site:https://t.co/ot37MtmKwp

#T1D #type1diabetes #OpenAPS #diabetes

[Breakthrough T1D @BreakthroughT1D]

BREAKING NEWS: @viacyte and CRISPR announced they are starting a clinical trial for VCTX210, a gene-edited cell replacement therapy for #T1D. Visit the link below for more information on this exciting news!

https://t.co/Y3mDOo03j9

[DiabeterResearch @DiabeterRes]

Disturbing Dutch stats: life expectancy of people with #T1D on average 13 years shorter. Dr HJ Aanstoot of Diabeter puts data into perspective: "After the shock of these data it's time for new developments and hope!" #type1diabetes #t1dcomplications https://t.co/Fjh6zN78Ju

[DiabeterResearch @DiabeterRes]

As part of the 'We Bike 2 Change Extremadura Challenge' van de #BasvandeGoor Foundation, a study was set up assessing how recent closed-loop #insulindelivery systems and adults with #T1D handle glucose management in physical activity situations https://t.co/ZJXSHYiMOh

[DiabeterResearch @DiabeterRes]

GAD-alum (vaccine for #T1D) was tested in the Diagnode-2 study (#Diabeter participated). It delays decrease in insulin producing capacity in people with T1D with HLA DR3-DQ2 haplotype, underscoring the need for personalized precision medicine approaches.
https://t.co/ayVUYKfka5

[DiabeterResearch @DiabeterRes]

2 new publications on https://t.co/sq2vxs08cT: Transferring #responsibility from #parents to children in #T1D https://t.co/vEbzVO6KJW & #AnxietyDisorders / #Mooddisorders in #adolescents with T1D https://t.co/KSIDJydAja #type1diabetes #depression #distress #diabetes

[DiabeterResearch @DiabeterRes]

First data of the #JDRF sponsored ‘#Biomarkers of #heterogeneity in #T1D’ study. In this cross-sectional analysis associations were found between residual
C-peptide production in people with T1D and impaired awareness of #hypoglycemia. #type1 #diabetes
https://t.co/xbP6JoM1UT

[Frontiers - Nutrition @FrontNutrition]

New Research: The Interplay Between Diet and the Epigenome in the Pathogenesis of Type-1 Diabetes: The autoimmune disease, Type 1 Diabetes Mellitus (T1DM), results in the destruction of pancreatic β-cells, and the International Diabetes… https://t.co/Ba3P8UFaUH #Nutrition

[Daniel J Drucker @DanielJDrucker]

Among our more popular articles of 2020, #mitochondria play critical roles in every cell, and are central to the pathophysiology of many metabolic disorders encountered in #endocrinology #metabolism #diabetes #obesity #exercise https://t.co/pB9bhvgeB2